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Background: Fibrillar amyloid-like deposits and co-deposits of tau and α-synuclein are found in several common
neurodegenerative diseases. Recent evidence indicates that small oligomers are the most relevant toxic aggregate
species. While tau fibril formation is well-characterized, factors influencing tau oligomerization and molecular
interactions of tau and α-synuclein are not well understood.
Results: We used a novel approach applying confocal single-particle fluorescence to investigate the influence of
tau phosphorylation and metal ions on tau oligomer formation and its coaggregation with α-synuclein at the level
of individual oligomers. We show that Al3+ at physiologically relevant concentrations and tau phosphorylation by
GSK-3β exert synergistic effects on the formation of a distinct SDS-resistant tau oligomer species even at nanomolar
protein concentration. Moreover, tau phosphorylation and Al3+ as well as Fe3+ enhanced both formation of mixed
oligomers and recruitment of α-synuclein in pre-formed tau oligomers.
Conclusions: Our findings provide a new perspective on interactions of tau phosphorylation, metal ions, and the
formation of potentially toxic oligomer species, and elucidate molecular crosstalks between different aggregation
pathways involved in neurodegeneration.
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Parkinson’s diseaseBackground
Several neurodegenerative diseases comprise neuronal or
glial deposits consisting mainly of protein tau, such as
Alzheimer’s neurofibrillary tangles (NFTs) or Pick bodies,
and are therefore termed “tauopathies“. In Alzheimer’s
Disease (AD), tau exhibits pathological hyperphosphoryla-
tion [1,2], allowing both histological diagnosis by use of
tau antibodies against disease specific phosphorylation
sites [3,4] and, to a certain extent, even in vivo diagnosis
by determination of the protein’s phosphorylation status
in cerebrospinal fluid [5,6].* Correspondence: armin.giese@med.uniuenchen.de
1Center for Neuropathology and Prion Research,
Ludwig-Maximilians-Universität, Feodor-Lynen-Str. 23, 81377, Munich,
Germany
Full list of author information is available at the end of the article
© 2012 Nübling et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orOne of the most important tau kinases is Glycogen
Synthase Kinase 3β (GSK-3β), which has been shown to
create AD specific phospho sites on tau in vitro [7], in
cell culture [8,9] and in vivo [10,11]. Some [12,13] but
not all [14] authors reported increased GSK levels in AD
brains. GSK-3β is colocalized with NFTs [15], and the
distribution of its active form in AD brains coincides
with the appearance of tau pathology [16].
Tau phosphorylation by GSK-3β promotes the forma-
tion of paired helical filaments (PHF) in vitro [17-19],
though data concerning the relevance of this effect vary
[20]. An enhancing impact of GSK-3β on tau aggrega-
tion was also demonstrated in cell culture and in vivo
[21-23], supporting a possible role of this kinase in AD
pathogenesis. Furthermore, phosphorylation influences
metal ion induced tau aggregation. Several studiesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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induced aggregation [24,25] or even is a prerequisite for
such aggregation [26,27].
The influence of aluminium on tau aggregation has
been extensively studied, since the metal ion was shown
to induce NFT-like deposits in mammalian brain after
intracerebral injection [28]. Though aluminium levels
were found to be raised in AD hippocampus [29] and
the metal ion was colocalized with NFTs and early tau
deposits in brain sections [30,31], its relevance to AD
pathogenesis is still unclear, especially due to the incon-
sistent outcome of epidemiological studies [32].
In vitro studies examining effects of ferric iron (Fe3+)
yielded results resembling those obtained for aluminium.
Fe3+ also induces the aggregation of phosphorylated
protein tau [27], is colocalized with NFTs [30,33,34] and
elevated in AD hippocampus and amygdala [35]. Fur-
thermore, Fe3+ induces α-synuclein (α-syn) aggregation
[36-38].
Co-deposits of tau and α-syn have been found in sev-
eral neurodegenerative diseases, and interactions be-
tween these two proteins recently gained increasing
interest. α-Syn has been detected in NFTs of AD, pro-
gressive supranuclear palsy (PSP) and corticobasal de-
generation (CBD) [39], whereas tau was located in Lewy
bodies of patients with Dementia with Lewy bodies
(DLB) [40]. In vitro, tau in solution requires inducers
like heparin for filament formation, whereas the protein
readily polymerizes in presence of α-syn without indu-
cers [41].
Furthermore, the minimal α-syn concentration neces-
sary for fibril formation is reduced in presence of tau,
and some of the fibrils formed in presence of both pro-
teins comprise tau and α-syn segments [41]. Consider-
ing that both proteins are located in the cytoplasmic
compartment of neurons, and that minimal concentra-
tions of α-syn oligomers can cross-seed tau aggregation
[42], interactions of tau and α-syn may be relevant for
pathological protein aggregation in neurodegenerative
diseases.
While established methods of monitoring tau and α-
syn aggregation like Thioflavin T assay or atomic force
microscopy yield important insights in fibril formation
and the formation of large oligomers, they are not suit-
able to directly monitor single protein interactions or
interactions of different proteins. It was demonstrated
that small oligomer species are on-pathway to tau fila-
ment formation [43]. Furthermore, it is increasingly
recognised that prefibrillar small oligomers rather than
the large NFTs might be responsible for neuronal and
synaptic loss [44-46]. To investigate the influence of
phosphorylation on tau oliomer formation and interac-
tions between tau and α-syn, we employed fluorescence
correlation spectroscopy (FCS) and scanning forintensely fluorescent targets (SIFT) to investigate the in-
fluence of phosphorylation and trivalent metal ions on
tau aggregation and its coaggregation with α-syn. These
methods allow monitoring of oligomerization processes
at the single molecule level even at nanomolar protein
concentrations [47,48]. Moreover, the possibility to label
proteins with different dyes allows the investigation of
tau and α-syn interactions at the level of individual
oligomers.
Results
Tau phosphorylation verified by western blot and SIFT
Mass spectroscopy showed that recombinant protein tau
is of high purity and does not contain significant
amounts of cleavage products (Figure 1A). Notably,
fluorescence labeling of tau with Alexa dyes did not alter
the protein’s electrophoretic mobility, though mass spec-
troscopy showed an increase in tau’s molecular weight
after labeling (data not shown). We confirmed in vitro
phosphorylation of human recombinant tau by demon-
strating a typical band shift of the protein in western
blot (see Figure 1B) [17]. We further evaluated whether
the SIFT method can be employed to detect phosphory-
lated protein tau by labeling with Alexa-488 tagged anti-
bodies AT-8 and T46. While T46 detects both
phosphorylated and unphosphorylated tau, the AT-8
antibody requires the protein to be phosphorylated at
specific sites (Goedert et al, 1995). The Aβ specific anti-
body 6E10 was used as a negative control. SIFT analysis
shows that both T46488 and AT-8488, but not 6E10488
bind to phosphorylated tau647 (pTau, Figure 1C), while
only T46488 binds to mock phosphorylated tau647
(mTau, also see materials and methods section).
Influence of phosphorylation on tau aggregation induced
by aluminium and DMSO
Our previous studies revealed that the organic solvent
DMSO and the metal ion aluminium (Al3+) induce the
formation of distinct tau oligomer species [49]. In order
to evaluate the influence of protein phosphorylation on
the effects of these aggregation inducers, we employed
GSK-3β to create phosphorylated tau (pTau) and com-
pared its aggregation behavior to mock phosphorylated
tau (mTau). Our findings show that oligomerization of
both pTau and mTau can be induced by 1% DMSO, with
mTau showing a higher rate of aggregation than pTau
(p< 0.001, Figure 2A). Conversely, in presence of 10 μM
Al3+, pTau oligomerization exceeds mTau (p< 0.05),
with the overall aggregation level being distinctly higher
compared to DMSO for both pTau and mTau (also see
Additional files 1 and 2).
2D histograms of detected aggregates show the forma-
tion of distinct oligomer species in presence of DMSO
and Al3+ (Figure 2B). In presence of DMSO, tau protein
Figure 1 (See legend on next page.)
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Figure 1 Tau phosphorylation verified by western blot and SIFT analysis. A. Mass spectroscopy showed that recombinant human tau
(isoform 5, 42967 Da) is of high purity. B. While mock phosphorylation (mTau) does not influence SDS-PAGE mobility of recombinant tau, a
typical band shift is observed upon tau phosphorylation (pTau). C. SIFT analysis showed labeling of pTau oligomers with the phosphorylated tau
specific AT-8 antibody in presence of 1% DMSO indicating antibody binding, while no coaggregation was observed with mTau. Data was
normalized against the coaggregation level of mTau with the T46 antibody, which does not require tau phosphorylation. 2D histograms
depicting antibody (x-axis) and protein (y-axis) interactions show coaggregates of T46 with both pTau and mTau, while AT-8 only coaggregates
with pTau. A scheme describing the appearance of mixed aggregates in 2D histograms is included in Figure 3. Upon combining AT-8 and mTau,
only DMSO induced tau aggregates are visible along the y-axis, similar to the control antibody 6E10. Measurements were taken from 12
independent samples; each sample was measured four times. Levels of significance are displayed as * = p< 0.05; ** = p< 0.01; {=p< 0.001.
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the formation of larger oligomers with higher fluores-
cence intensity.
Fluorescence intensity distribution analysis (FIDA) of
tau oligomers induced by DMSO yielded larger aggre-
gates for mTau (mean 76 molecules) than for pTau
(mean 26 molecules). In presence of Al3+, large tau oli-
gomers comprising on average 240 (pTau) and 220
(mTau) molecules occurred within 15 minutes, while the
overall aggregation level was higher for pTau (Figure 2A,
for aggregation dynamics also see Additional file 3). The
combination of DMSO and Al3+ increased aggregation
levels compared to Al3+ alone predominantly for mTau
(also see Additional files 1 and 2).
Furthermore, we examined the SDS stability of oligo-
mers generated by the different enhancers (Figure 2C,
D). While DMSO induced aggregates dissolve upon
addition of the ionic detergent SDS in a final concentra-
tion of 0.2%, more than 50% of the Al3+ induced oligo-
mer signal remains stable 100 min after addition of SDS.
In conclusion, Al3+ promotes rapid formation of deter-
gent resistant oligomers, preferably of phosphorylated
protein tau. Conversely, DMSO induced aggregation is
diminished upon tau phosphorylation.Influence of tau phosphorylation on the coaggregation of
monomeric tau and α-synuclein in presence of metal ions
and organic solvents
Since the role of tau and α-syn coaggregation is increas-
ingly recognized, we investigated the effect of tau488
phosphorylation on its coaggregation with α-syn647. As
previous work has shown a major influence of Fe3+ on
α-syn oligomerization [36-38], we also used Fe3+ at a
final concentration of 10 μM in our assay.
In these experiments, 1% DMSO promoted the coag-
gregation of tau and α-syn in a similar manner for pTau
and mTau (Figure 3A). On average, coaggregates were
composed of 11 pTau + 8 α-syn monomers or 15 mTau+
12 α-syn monomers, respectively, as determined by
FIDA analysis. Fe3+ also had a promotional influence on
coaggregation, which was higher for pTau (p< 0.01, on
average 53 pTau + 10 α-syn and 39 mTau+ 3 α-syn
monomers per oligomer). Upon combining DMSO andFe3+, an additional effect exceeding the influence of one
inducer alone can be seen (also see Additional files 4
and 5), while no significant difference in aggregation
levels of pTau and mTau was detectable. Similar to our
tau oligomerization experiments, Al3+ was the strongest
inducer of tau and α-syn coaggregation, with pTau
showing higher coaggregation activity than mTau (p<
0.001, Figure 3A; on average 131 pTau + 115 α-syn and
137 mTau + 80 α-syn monomers per oligomer). This dif-
ference was still detectable when combining Al3+ with
DMSO, though to a lesser extent (p< 0.05). Mixed oli-
gomers comprising both tau and α-syn appear scattered
around the bisectrix of these histograms, while homoge-
neous aggregates are located close to the axes, as illu-
strated in Figure 3D.
Concerning oligomer stability, 0.2% SDS reduced the
number of coaggregates formed in presence of every
tested agent (Figure 3B, C). Again, coaggregates formed
in presence of metal ions proved to be more resistant to
SDS than those induced by DMSO, though to an overall
lesser extent than the homogeneous tau aggregates.
Oligomer sizes before and after addition of SDS as deter-
mined by FIDA analysis are provided in Additional file
6. The presence of Al3+-induced, SDS stable mixed oli-
gomers was further validated applying gel filtration and
fluorescence spectroscopy. In these experiments, Al3+
induced oligomers were separated from monomers by
gel filtration. SDS stable mixed tau and α-syn oligomers
eluted prior to monomers, as demonstrated by cross-
correlation and SIFT-2D analysis (see Additional file 7).
Thus, our data show increased tau and α-syn coaggre-
gation after tau phosphorylation in presence of trivalent
metal ions, and that the heterogenic oligomers generated
by Fe3+ and Al3+ are more stable to SDS treatment than
those formed by DMSO.Coaggregation of tau oligomers and monomeric
α-synuclein
Giasson et al. showed that tau and α-syn induce each
other’s filament formation, and that some of the fibrils
formed in presence of both proteins comprise tau and
α-syn segments [41]. Such findings suggest that these
segments are either assembled by end to end annealing
Figure 2 (See legend on next page.)
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Figure 2 Al3+ promotes the formation of SDS stable tau oligomers more efficiently after tau phosphorylation. A. Cross-correlation
amplitudes (G (0)) show mild proaggregatory activity of the organic solvent DMSO, which was significantly higher for mTau. Al3+ promotes
intense protein oligomerization. Measurements were taken from 15 independent samples; each sample was measured four times. B. 2D
histograms of detected photons indicate the formation of smaller oligomers in presence of DMSO (mean 76 monomers per oligomer for mTau,
26 monomers for pTau) compared to Al3+ (mean 220 to 240 monomers per oligomer). C. Cross correlation amplitude immediately before (T0)
and 100 min after (T100) addition of SDS to the aggregation assay. Significant reductions of aggregation levels at T100 are indicated by the
symbols over the error bars, while significant differences between pTau and mTau are indicated by the symbols over the wide bars.
Measurements were taken from 7 independent samples. D. Cross correlation amplitude at T100 normalized against T0 shows increased SDS-
resistance of Al3+ induced oligomers compared to DMSO. Levels of significance are displayed as * = p< 0.05; ** = p< 0.01; {=p< 0.001.
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as seeds for both proteins. To evaluate the effect of tau
phosphorylation on the interaction of tau oligomers with
monomeric α-syn, tau488 was first incubated in presence
of 1% DMSO, 10 μM Fe3+, 10 μM Al3+, and combina-
tions of these agents for 90 minutes to generate pre-
formed tau oligomers. α-Syn647 monomers were then
added to the assay and measurements were conducted
(Figure 4A).
Contrary to the experiments with tau monomers,
DMSO had a stronger effect on the coaggregation of
pre-formed mTau oligomers with monomeric α-syn
compared to pTau oligomers (p< 0.05, Figure 4A).
Under these conditions, coaggregates contained on aver-
age 20 pTau + 2 α-syn monomers or 27 mTau+ 5 α-syn
monomers, respectively.
pTau oligomer coaggregation with monomeric α-syn
exceeded mTau seven- to ninefold in presence of Fe3+
(p< 0.01; on average 197 pTau + 14 α-syn or 175 mTau+
3 α-syn monomers per oligomer) and Al3+ (p< 0.001;
on average 151 pTau + 73 α-syn or 154 mTau+ 35 α-syn
monomers per oligomer). This difference was markedly
reduced upon combining Fe3+ and 1% DMSO, which
again yielded a synergistic effect compared to the two
inducers alone (also see Additional files 8 and 9). The
combination of Al3+ and 1% DMSO also reduced the dif-
ference between pTau and mTau to a two-fold excess of
pTau coaggregation (p< 0.01).
SDS (0.2%) reduced the number of oligomers formed
in presence of every tested inducer (Figure 4B). Espe-
cially aggregates induced by metal ions alone showed
enhanced resistance to SDS treatment compared to
those formed in presence of DMSO (Figure 4C).Discussion
Several studies have dealt with the influence of protein
phosphorylation and the metal ion aluminium (Al3+) on
tau filament formation so far [17-27]. However, the
pathophysiological relevance of these factors is still un-
clear. Whereas most studies were mainly focused on tau
filament formation, we applied single molecule fluores-
cence techniques to investigate the influence of these
factors on early tau aggregation steps and oligomerformation. We demonstrate that tau phosphorylation
modulates oligomer formation in presence of Al3+, and
that Al3+ induces the formation of distinct large, SDS re-
sistant tau oligomers.
We further demonstrate that coaggregation of tau and
α-syn can be observed at the single molecule level, is dif-
ferentially modulated by tau phosphorylation, and
induced by trivalent metal ions. Such coaggregation might
be of pathophysiological relevance, since co-deposits of
tau and α-syn have been detected in various neurodegen-
erative diseases [39,40].
Influence of tau phosphorylation on electrophoretic
mobility and antibody interaction
It has been demonstrated that in vitro phosphorylation
of human protein tau by GSK-3β can be verified using
SDS-PAGE by demonstrating a complete band shift of
phosphorylated tau compared to the unphosphorylated
protein [17]. We verified efficient tau phosphorylation
indicated by a complete band shift compared to the
unphosporylated protein (Figure 1B). In addition, we
investigated whether fluorescently labeled antibodies can
be employed in the SIFT method to verify tau phosphor-
ylation at nanomolar protein concentrations, allowing
for possible diagnostic implementations of this method
in the future. Our data corroborate that tau phosphoryl-
ation was successful and that antibodies can be
employed in the SIFT method to identify proteins and
posttranslational modifications such as phosphorylation
at nanomolar protein concentrations (Figure 1C). Such
an assay may provide a valuable tool for future diagnos-
tic applications e.g. the detection of novel specific CSF
biomarkers of neurodegeneration.
Differential influence of phosphorylation on tau
aggregation
In vitro studies have yielded conflicting results regarding
the influence of tau phosphorylation on its assembly to
filaments. To date, both inhibitory and promotional
effects of GSK-3β mediated phosphorylation on tau fila-
ment assembly were found in absence or presence of
polyanionic aggregation inducers [17-20,50,51]. Notably,
for Al3+ induced tau aggregation, phosphorylation was
Figure 3 (See legend on next page.)
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ments, even a prerequisite [24-27].
However, the methods applied in these studies, such as
electron microscopy, thioflavine fluorescence, laser lightscattering, SDS-PAGE and western blot, are of limited use
in directly examining single molecule interactions at the
oligomer level. Furthermore, these techniques often re-
quire high concentrations of both protein and aggregation
(See figure on previous page.)
Figure 3 Al3+ promotes stronger formation of SDS stable tau and α-syn coaggregates than Fe3+, preferably after tau phosphorylation.
A. Cross-correlation amplitudes (G (0)) show mild proaggregatory activity of DMSO and Fe3+, while Al3+ promotes intense protein
oligomerization. Combinations of DMSO and metal ions show a synergistic effect especially for mTau. 2D histograms show the formation of
smaller oligomers induced by DMSO compared to Al3+. B. Cross-correlation amplitude before (T0) and 100 min after (T100) addition of SDS to the
aggregation assay. Significant reductions of aggregation levels at T100 are indicated by the symbols over the error bars, while significant
differences between pTau and mTau are indicated by the symbols over the wide bars. C. Cross correlation amplitude at T100 normalized against
T0 shows increased SDS-resistance of metal ion induced oligomers compared to DMSO. D. Scheme illustrating the appearance of tau and α-syn
aggregates and coaggregates of the two proteins. Higher fluorescence intensities of detected oligomers indicate increased oligomer size.
Measurements were taken from 16 independent samples; each sample was measured four times. Levels of significance are displayed as
* = p< 0.05; ** = p< 0.01; {=p< 0.001.
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pecially given the fact that tau protein readily polymerizes
at high concentrations without any inducer [52,53]. In
addition, the majority of studies investigating brain Al3+
concentrations did not detect concentrations exceeding 10
μg/g brain mass (dry weight) in AD brains [54], which ap-
proximately corresponds to 60 μmol/kg (wet weight),
while many studies examining the influence of Al3+ on tau
aggregation in vitro applied Al3+ concentrations in the
milimolar range [25,27,55].
In this study, we applied confocal single molecule fluor-
escent techniques to investigate the influence of protein
phosphorylation by GSK-3β on tau oligomer formation at
the single molecule level at nanomolar concentrations. Ex-
posure to 10 μM Al3+ induced the rapid formation of large
tau oligomers, while DMSO at a final concentration of 1%
led to the formation of smaller oligomers. The large Al3+
triggered oligomers contained an average of 220 to 240
molecules as shown by FIDA analysis, and were resistant
to treatment with 0.2% SDS, which in contrast readily dis-
solved the smaller oligomers formed in presence of
DMSO. The oligomer sizes observed here were compar-
able with data presented earlier [49]. Interestingly, phos-
phorylation by GSK-3β yielded an increase in Al3+
induced tau oligomer formation, while oligomer size was
comparable for pTau and mTau.
Thus, our data identify tau phosphorylation and
physiological concentrations of the metal ion Al3+ as
synergistic inducers of the formation of SDS resistant
tau oligomers even at nanomolar protein concentrations.
These findings substantiate the hypothesis that Al3+ may
play a role in the formation of neurotoxic oligomers
even at early stages of neurodegeneration.
Metal ions and organic solvents enhance tau and
α-synunclein coaggregation depending on tau’s
phosphorylation status
Co-deposits of tau and α-syn have been found in several
neurodegenerative diseases, including AD, PSP, CBD and
DLB [39,40]. Since interactions of different proteins are
difficult to monitor in vitro, only few studies investigating
the interaction of tau and α-syn have been published sofar. It was demonstrated that in mixed micromolar solu-
tions of α-syn and tau, both proteins’ minimal concentra-
tions for filament assembly are decreased [41,56].
Moreover, Giasson et al. detected filaments that comprised
both tau and α-syn, proving that the two proteins directly
interact in mixed solutions [41]. A more recent study
showed that α-syn fibrils can be taken up by tau overex-
pressing cells and induce the formation of phosphorylated
triton-insoluble tau oligomers [57]. In vivo studies further
demonstrated that tau deposits can be found in mice over-
expressing pathologic human α-syn mutations [58].
In this study, we demonstrate that coaggregation of
tau and α-syn takes place even at nanomolar protein
concentrations, is strongly induced by trivalent metal
ions, and differentially modulated by tau’s phosphoryl-
ation status. In contrast to the findings of Giasson et al.,
we did not detect tau and α-syn coaggregation in the ab-
sence of aggregation inducers. This apparent discrepancy
is most likely explained by the differences in protein
concentrations (up to 1000-fold) and the shorter obser-
vation time [41]. However, our data demonstrate that
tau and α-syn coaggregation occurs even at nanomolar
protein concentrations in presence of aggregation indu-
cers. As in our tau aggregation assay, Al3+ had the most
pronounced effect on coaggregation of α-syn with tau
monomers and oligomers. Al3+ induces rapid coaggrega-
tion of tau and α-syn (see Additional file 3). Fe3+ and
DMSO also induce coaggregation of the two proteins,
though to an overall lesser extent. In our experiments,
tau phosphorylation by GSK-3β strongly enhanced the
formation of mixed oligomers induced by Al3+ or Fe3+.
Moreover, the mixed oligomers resulting from metal ion
induced coaggregation proved to be more resistant to
SDS treatment than those formed in presence of DMSO.
We further provide data from FIDA analysis and gel
filtration experiments demonstrating the presence and
size of mixed tau and a-syn oligomers (see Additional
files 6 and 7). Earlier studies applying atomic force mico-
scropy and SIFT established FIDA-based quantification
of oligomer sizes as a reliable method [38].
These results extend the current model of tau and
α-syn interaction at early stages of neurodegeneration.
Figure 4 Monomeric α-syn preferably coaggregates with pTau oligomers in presence of metal ions. A. Cross-correlation amplitudes (G (0))
show mild coaggregation of α-syn monomers with pre-formed tau oligomers induced by DMSO and Fe3+, while Al3+ promotes intense
coaggregation. Combinations of DMSO and metal ions show a synergistic effect especially for mTau. 2D histograms show the formation of
smaller mixed oligomers induced by DMSO compared to the metal ions. B. Cross-correlation amplitude before (T0) and 100 min after (T100)
addition of SDS to the aggregation assay. Significant reductions of aggregation levels at T100 are indicated by the symbols over the error bars,
while significant differences between pTau and mTau are indicated by the symbols over the wide bars. C. Cross correlation amplitude at T100
normalized against T0 shows increased SDS-resistance of metal ion induced oligomers compared to DMSO. Measurements were taken from 20
independent samples; each sample was measured four times. Levels of significance are displayed as * = p< 0.05; ** = p< 0.01; {=p< 0.001.
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α-syn is low in pre-clinical neurodegeneration, the
presence of pro-aggregatory factors may be crucial in
the generation of early mixed oligomers. We identify tri-
valent metal ions and tau phosphorylation by GSK-3β as
potential inducers of such oligomer formation even at
nanomolar protein concentrations. A time-dependent
increase of oligomer concentrations may then induce
self-propagating and cross-seeding mechanisms as
demonstrated by Giasson and Waxman [41,57].
Conclusions
In summary, we demonstrate that tau phosphorylation
and trivalent metal ions such as Al3+ act together in the
formation of distinct SDS resistant tau oligomers. More-
over, applying confocal single molecule fluorescence
techniques, we show that, under certain conditions,
interactions of tau and α-syn can take place even at
nanomolar protein concentrations, and result in the for-
mation of mixed oligomers. Notably, the formation of
SDS resistant mixed aggregates was induced by physiolo-
gically relevant concentrations of trivalent metal ions,
and strongly enhanced by tau phosphorylation. Taking
into account that a considerable amount of soluble tau
exists in a phosphorylated state in neurodegenerative
diseases [1,2,59], these findings support a crucial role of
specific metal ions such as Al3+ and Fe3+ in early cyto-
plasmic aggregation and coaggregation events.
Moreover, our results indicate common pathophysio-
logic mechanisms of both tau aggregation and cross-
seeding phenomena, and might explain the coincidence
of tau and α-syn in neuronal deposits. The mixed aggre-
gates described here may provide an interlink of differ-
ent pathological pathways leading to neurodegeneration,
and may serve as promising therapeutic targets for fu-
ture drug development. Furthermore, we introduce a
novel technique of monitoring post-translational modifi-
cations at very low protein concentrations that may pro-
vide a powerful diagnostic tool in the future.
Methods
Expression of human proteins tau and α-synuclein
Protein tau
Tau isoform 5 was expressed in E.coli as described previ-
ously [49]. In brief, thermocompetent E.coli DE3 (RIL)
were transformed, and tau was purified by sterile filtra-
tion, cation exchange chromatography and ammonium
acid salt precipitation. The transformation vector was a
kind gift of Manuela Neumann (ZNP Munich/Zurich).
α-Synuclein
α-Synuclein was produced according to established proto-
cols [48]. A stock solution containing 1 mg/ml α-synuclein
was prepared in 50 mM tris buffer, pH 7.0.Protein labeling
Proteins were labeled with fluorescent dyes Alexa-488-O-
succinimidylester and Alexa-647-O-succinimidylester, re-
spectively, as described previously [48]. Tau isoform 5 was
incubated with a four-fold molar excess of Alexa-488 or
Alexa-647 in 100 mM NaHCO3 for 24 h at room
temperature. For α-syn, a two-fold molar excess of dye
was used. Antibodies T46 (Invitrogen, Carlsbad, CA), AT-
8 (Pierce Endogen, Rockford, IL) and 6E10 (Acris Anti-
bodies, Hiddenhausen, Germany) first underwent buffer
exchange to PBS pH 7.0. Since antibody concentrations
after buffer exchange were unknown, concentrations of
Alexa-488-O-succinimidylester were determined empiric-
ally. Unbound dye was separated using a PD10 desalting
column. Fluorescently labeled proteins are further referred
to as tau488, tau647, and α-syn647.
Phosphorylation of protein tau
Tau phosphorylation was conducted as described previ-
ously [17]. Fluorescently labeled protein tau was incu-
bated with Glycogen Synthase Kinase 3β (Sigma, Saint
Louis, MO) in a ratio of 0,018 U GSK-3 β / pmol tau in
buffer containing 33 mM tris pH 7.5, 40 mM hepes pH
7.64, 100 mM NaCl, 5 mM EGTA, 3 mM MgCl2, 2 mM
ATP, 180 mM sucrose, 0.13 mM PMSF, 0.67 mM benza-
midine, 0.067% mercaptoethanol and 0.02% Brij-35.
Samples were incubated for 20 h at 30 °C under constant
shaking. As control, fluorescently labeled protein tau
was incubated in buffer containing all components ex-
cept for the enzyme, and is further referred to as mock
phosphorylated tau (mTau). Protein phosphorylation was
confirmed by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and western blot using
antibody T46 as described previously [60]. Phosphory-
lated protein tau (pTau) featured a typical band shift
compared to mTau, as described previously [17]
(Figure 1B).
Aggregation assay
Stock solutions of tau488, tau647, and α-syn647 were pre-
pared for a final concentration of 10 molecules per focal
volume, equivalent to a concentration of 10 nM to 20
nM. For coaggregation experiments, a 1:1 ratio of tau488
and α-syn647 was used. Prior to each experiment, tau
samples were centrifuged at 100.000 g for 30 min to re-
move pre-formed aggregates, and all protein stock solu-
tions were then controlled for pre-existing aggregates by
SIFT [49]. Only samples free of pre-formed aggregates
were used. All experiments were conducted in 96 well
plates with a cover slide bottom, in a total sample vol-
ume of 20 μl per well. Plates were covered with adhesive
film to obviate evaporation. For aggregation and coag-
gregation experiments, protein stock solutions were
added to wells containing 50 mM tris buffer pH 7.0, 10
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(DMSO), and measurements were started immediately.
For coaggregation of tau488 oligomers with α-syn647
monomers, samples of tau488 were prepared as described
above and pre-incubated for 90 min. Subsequently, α-
syn647 monomers were added and measurements were
started immediately. To investigate oligomer stability, a
10-fold SDS stock solution for a final concentration of
0.2% was added to each well after each experiment, and
measurements were repeated. Each well was measured
four times, resulting in a total duration of each experi-
ment of 60 to 120 minutes, depending on experimental
layout.
Confocal single particle analysis
FCS and SIFT were performed on an InsightReader
(Evotec-Technologies, Hamburg, Germany) with dual
color excitation at 488 and 633 nm as described previ-
ously [48,49,61]. Data was collected separately for each
excitation wavelength by two single-photon detectors.
Analysis was performed using FCSPP evaluation soft-
ware version 2.0 (Evotec-Technologies), allowing auto-
correlation, cross-correlation and fluorescence intensity
distribution (FIDA) analysis, and SIFT-2D evaluation
software (Evotec-Technologies). For SIFT-2D analysis,
photons were added up in time intervals (bins) of 40 μs
and illustrated in a 2D scatterplot. Scatterplots depicted
in this paper contain all photons of all consecutive mea-
surements of one sample. Photon-weighted SIFT aggre-
gation and coaggregation analysis was performed as
described previously [49]. As cross-correlation detects
small oligomeric protein aggregates with higher sensitivity,
only cross-correlation data is depicted for experiments on
tau aggregation and coaggregation with α-syn (for SIFT
data see Additional files 1, 4, and 7).
Mass spectroscopy
Mass spectroscopy was performed according to estab-
lished protocols to verify the purity of tau protein stock
solution [61].
Statistical analysis
Normal distribution of data was determined by Shapiro-
Wilk test. If normal distribution was confirmed, a two-
sided student’s t-test preceded by Levene’s test for equality
of variance was performed. A paired student’s t-test was
used for experiments on SDS-resistance of oligomers. If
normal distribution was not confirmed, Mann–Whitney
U-test was performed. Bonferroni-adjustment for multiple
testing was done where appropriate. Data is demonstrated
as average of all independent samples, and a paired stu-
dent’s t-test was performed including all independent
samples. Error bars in figures show the standard error of
the mean.Additional files
Additional file 1: Comparison of aggregation levels of pTau and
mTau. Comparison of aggregation levels of phosphorylated (pTau) and
mock phosphorylated (mTau) protein tau in presence of different
aggregation inducers. SIFT data is presented as ratios (colum / row).
Measurements were taken from 15 independent samples, each sample
was measured four times.
Additional file 2: Comparison of aggregation levels of pTau and
mTau. Comparison of aggregation levels of phosphorylated (pTau) and
mock phosphorylated (mTau) protein tau in presence of different
aggregation inducers. Cross-correlation data is presented as ratios (colum /
row). Measurements were taken from 15 independent samples, each
sample was measured four times.
Additional file 3: Kinetics of pTau and mTau aggregation and
coaggregation. Kinetics of pTau and mTau aggregation (tau/tau, 15
independent samples) and coaggregation of tau monomers (tau/α-syn,
16 independent samples) and oligomers (tauoligo/α-syn, 20
independent samples) with monomeric α-synuclein in presence of 1%
DMSO, 10 μM Al3+, 10 μM Fe3+ and combinations of metal ions and
DMSO. A control measurement depicting the aggregation status in the
absence of inducers was defined as time point “0". While DMSO
induces slow continuous tau aggregation, the protein’s coaggregation
with α-syn reaches an early steady state. Al3+ promotes rapid initial
aggregation and coaggregation only for pTau, while mTau
coaggregation proceeds distinctly slower. Fe3+ induced coaggregation
is continuous, with pTau proceeding faster than mTau. Upon
combining metal ions and DMSO, both pTau and mTau show rapid
aggregation and coaggregation exceeding the single inducers.
Levels of significance are displayed as * = p< 0.05; ** = p <0.01;
{= p< 0.001.
Additional file 4: Comparison of coaggregation levels of pTau
and mTau with α-syn. Comparison of coaggregation levels of
phosphorylated (pTau) and mock phosphorylated (mTau) protein tau
with α-synuclein in presence of different aggregation inducers. SIFT
data is presented as ratios (colum / row). Measurements were taken
from 16 independent samples, each sample was measured four times.
Additional file 5: Comparison of coaggregation levels of pTau
and mTau with α-syn. Comparison of coaggregation levels of
phosphorylated (pTau) and mock phosphorylated (mTau) protein tau
with α-synuclein in presence of different aggregation inducers. Cross-
correlation data is presented as ratios (colum / row). Measurements
were taken from 16 independent samples, each sample was measured
four times.
Additional file 6: Quantification of mixed tau and α-syn oligomer
sizes. Fluorescence intensity distribution analysis (FIDA) shows the size
of metal ion induced mixed tau and α-syn oligomers before and after
addition of SDS. SDS stable mixed oligomers can further be
demonstrated in SIFT-2D analysis.
Additional file 7: Separation of SDS stable mixed tau and α-syn
oligomers by gel filtration. Mixed tau and α-syn oligomers induced by Al3+
are separated from monomers applying gel filtration. SDS-stable oligomers
are eluted before tau and α-syn monomers, as demonstrated by cross-
correlation and SIFT analysis.
Additional file 8: Comparison of coaggregation levels of pTau and
mTau oligomers with α-syn. Comparison of coaggregation levels of
phosphorylated (pTau) and mock phosphorylated (mTau) tau
oligomers with monomeric α-synuclein in presence of different
aggregation inducers. SIFT data is presented as ratios (colum / row).
Measurements were taken from 20 independent samples, each sample
was measured four times.
Additional file 9: Comparison of coaggregation levels of pTau
and mTau oligomers with α-syn. Comparison of coaggregation
levels of phosphorylated (pTau) and mock phosphorylated (mTau) tau
oligomers with monomeric α-synuclein in presence of different
aggregation inducers. Cross-correlation data is presented as ratios
(colum / row). Measurements were taken from 20 independent
samples, each sample was measured four times.
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FCS: Fluorescence correlation spectroscopy; FIDA: fluorescence intensity
distribution analysis; GSK-3β: Glycogen synthase kinase 3β; mTau: Mock
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